Critical Outcome - Investor Presentation - January 2014

Click here to load reader

Embed Size (px)

Transcript of Critical Outcome - Investor Presentation - January 2014

  • 1.The future of drug discovery has arrivedTSX-V: COT | January 2014

2. Disclaimer When used anywhere in this presentation, whether oral or written, the words expects, believes, anticipates, estimates and similar expressions are intended to identify forward-looking statements. Forward-looking statements may include statements addressing future financial and operating results of Critical Outcome Technologies Inc. (COTI). COTI bases these forward-looking statements on its current expectations about future events. Such statements are subject to risks and uncertainties including, but not limited to, the successful implementation of COTIs strategic plans, the acceptance of new products, the obsolescence of existing products, the resolution of potential patent issues, competition, changes in economic conditions, and other risks described in COTIs public documents such as press releases and filings with the Toronto Stock Exchange and the Ontario Securities Commission. All forward-looking statements are qualified in their entirety by the cautionary statements included in this document and such filings. These risks and uncertainties could cause actual results to differ materially from results expressed or implied by forward-looking statements contained in this presentation. These forward-looking statements speak only as of the date of this presentation. 2 3. Who we are A bioinformatics and accelerated drug discovery company Established in 2005 Listed on the TSX-V under the symbol COT3 4. Investment highlights1We reduce the time, cost & risk of bringing new drugs to market2Scalable platform technology enables multiple concurrent projects3Potential cancer breakthrough is (nearly) Phase 1 ready4 5. What we do Reduce drug discovery, optimization & lead selection by 1.5 to 3 yrs. Saving significant $$$ Increasing revenue period under patent protection5 6. How we do it CHEMSAS Proprietary platform technology Artificial intelligence + proprietary algorithms + medicinal chemistry expertise 6 7. Advantages of CHEMSAS Computational replication of traditional wet lab drug discovery process Failed attempts occur quickly & cheaply in computer simulations, not the research bench Higher probability of clinical & commercial success7 8. Scalable platform technology Enables multiple concurrent revenue opportunities 3 existing R&D collaborations - Western University - Delmar Chemicals - Major Pharma Co. Collaborations expected to bring in multiple milestone payments beginning late 2014 / 2015 8 9. Scalable platform technology Robust internal pipeline of compounds COTI-2, AML, etc. Strategy to license our own compounds Upfront payments, milestones, royalties9 10. Potential cancer breakthroughOur lead compound, COTI2, is effective against cancers with mutations of the p53 gene10 11. > 50% of all human cancers have a p53 mutation (eg. ~95% of ovarian cancers)Why COTI-2 is excitingMechanism of action confirmed by thought leader Dr. Gordon Mills at MD Anderson Cancer Center (June 2013)Novel, first in class Strong IP protection in place 11 12. COTI-2 is (nearly) Phase 1 ready In final 2-species toxicity studies completion in first half of 2014 FDA filing expected mid-to-late 2014 (leading to Phase 1 clinical trial) Pursuing orphan drug &/or breakthrough therapy status Seeking optimal partner for clinical development 12 13. COTI-2 = significant revenue potential Top 5 2012 Phase 1/2 oncology licensing deals disclosed (1): Upfront payments of approx. $25-$92 million Milestone payments between $550-$1,100 million Royalties on net sales 1st half of 2013 (2) 16 phase 1 licensing deals with 6 in cancer avg. upfront $30m(1) (2)Medius Associates Thomson Reuters13 14. Looking ahead: Project ROSALIND Programmable computer simulation of human cancer cell signaling Better personalized treatment decisions based on genetic profile of ones cancer Personalized cancer gene profiling projected to be * ~$35B market by 2018*Markets and Markets (2013)14 15. The future of drug discovery has arrivedDr. Wayne Danter President & CEO Tel: (519) 858-5157 [email protected]